Media Contact:
Nicole Osmer
nicole@nicoleosmer.com
(650) 454-0504

Tryton Announces TCT Activities
Symposium to Feature Interim Six-Month Results from More Than 250 Patients Treated with Tryton Stent System

Durham, N.C. – Sept. 17, 2010 – Tryton Medical, Inc., the leading developer of stents designed to definitively treat bifurcation lesions, today announced that the company will sponsor a symposium on Thursday, Sept. 23, 2010 during the Transcatheter Cardiovascular Therapeutics (TCT) 2010 conference in Washington, D.C.

Interim six-month results from more than 250 patients from the E-Tryton 150 and Benelux registries will be presented by David P. Foley, M.D., of Beaumont Hospital & Royal College of Surgeons in Ireland. The symposium will also feature additional presentations by David O. Williams, M.D. of Brigham and Women's Hospital in Boston, Mass.; Antonio L. Bartorelli, M.D. of the University of Milan; Robert-Jan van Geuns, M.D., of Erasmus University Heart Center University Hospital in Rotterdam, the Netherlands; and Aaron V. Kaplan, M.D., of Dartmouth-Hitchcock Medical Center in Lebanon, N.H.

"Current approaches to PCI of bifurcation lesions are diverse, and two-stent approaches in particular can increase complexity and risk of acute complications and restenosis down the line," said Prof. Foley. "The Tryton Side Branch Stent offers a simple and straightforward approach to first securing the side branch, allowing stenting of the main vessel using a conventional drug eluting stent. The Tryton solution has become an important part of my clinical practice, and I look forward to presenting additional data on the system at TCT."

The one-hour event begins at 2:00 p.m. and will take place in the Exhibit Hall Presentation Theater in the Washington Convention Center.

"We're pleased that the Tryton Side Branch Stent has helped physicians across Europe treat thousands of the most challenging interventional cases in cardiovascular disease," said J. Greg Davis, president and CEO of Tryton Medical. "We look forward to demonstrating the Tryton stent system at TCT next week."

In addition, Prof. Foley will discuss the Tryton system in his TCT presentation titled "The Tryton Stent: Better Than a Balloon, Equivalent to DES in the Side Branch?" which will take place on Tuesday, Sept. 21 at 11:42 a.m. in room 152AB.

Tryton will also exhibit at the conference at booth 1357.

TRYTON MEDICAL, INC.
1000 Park Forty Plaza, Suite 325
Durham, NC 27713

PHONE 919/226.1490
FAX 919/226.1497
info@trytonmedical.com

trytonmedical.com

The Tryton Side Branch Stent System is designed to offer a dedicated strategy for treating atherosclerotic lesions in the side branch at the site of a bifurcation. Tryton's highly deliverable cobalt chromium stent is deployed in the side branch artery using a standard single-wire balloon-expandable stent delivery system. A conventional drug-eluting stent is then placed in the main vessel.

Excellent Six-Month Clinical Results

The Tryton Side Branch Stent System demonstrated excellent six-month clinical and angiographic results in a first-in-man study of the system and excellent six-month clinical results from almost 200 patients in four different registries with a rate of target lesion revascularization of less than four percent.

The stent system has received CE Mark approval in Europe and is commercially available in 21 countries throughout Europe and the Middle East. It is not approved in the United States.

About Tryton Medical, Inc.

Tryton Medical, Inc., located in Durham, N.C., is a leading developer of novel stent systems for the treatment of bifurcation lesions. The company was founded in 2003 by Aaron V. Kaplan, M.D. (Professor of Medicine at Dartmouth Medical School/Dartmouth-Hitchcock Medical Center) and Dan Cole to develop stents for the definitive treatment of bifurcation lesions. The Tryton Side Branch Stent System, approved for sale in Europe, is designed to offer a dedicated strategy for treating these challenging cases. Privately held, Tryton is backed by Arnerich Massena & Associates, Spray Ventures, PTV Sciences, and RiverVest Ventures. For more information please visit www.trytonmedical.com.

# # #